Nociscan selected for inclusion in pivotal national institutes of health (nih) study for low back pain

Nih funded biomarkers for evaluating spine treatments (best) trial launching this quarter best to study the role of biomarkers in optimizing the treatment of chronic low back pain nociscantm to be commercially active across seven participating major academic medical centers broomfield, co / accesswire / september 19, 2022 / aclarion, inc., ("aclarion" or the "company") (nasdaq:acon)(nasdaq:aconw), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their participation in the biomarkers for evaluating spine treatments (best) trial funded through the helping to end addiction long-termsm initiative, or nih heal initiativesm. best will enroll over 800 patients at 12 leading academic teaching institutions across the united states, with a subset of 200 undergoing advanced biomarker profiling, which includes nociscan.
ACON Ratings Summary
ACON Quant Ranking